Participants should be aware of the following financial/non-financial relationships: Paul D. Rosenblit, MD, PhD, FNLA, FACE: Disclosure information not submitted.
Learning Objectives:
Discuss the role of non-traditional biomarkers and advanced lipid testing in improving ASCVD risk assessment.
Distinguish usefulness of selected biomarkers with respect to risk levels, or various clinical disease stages, or clinical states.
Describe how single or multiple non-traditional biomarker(s) are determined to add value for a significant improvement in ASCVD risk beyond standard risk factors.
